Wegovy Dosage Instructions: What the Titration Schedule Actually Means

The myth that faster titration means faster results

A question our prescribers hear most weeks is whether it is possible to skip the early Wegovy doses and move straight to 1.7mg or 2.4mg. The reasoning makes intuitive sense: if the higher doses are where most of the weight-loss effect happens, why spend months on the lower rungs?

The answer lies in how semaglutide interacts with the gut. GLP-1 receptor agonists slow gastric emptying and alter appetite signalling, and both effects can produce nausea, vomiting and digestive discomfort, particularly in the early weeks. The dose escalation is designed to give your gastrointestinal system time to adapt, reducing the severity of those side effects significantly. Compressing the schedule tends to amplify them, which in practice leads many people to pause treatment entirely or stop sooner than planned.

The NHS semaglutide medicines page describes the standard titration clearly and is a reliable first reference if you want to read the schedule alongside your Patient Information Leaflet. Clinical trials underpinning Wegovy's licence used this graduated approach throughout; the 15% average weight loss reported in STEP 1 reflects a population that followed it. Moving faster is not, in most cases, a shortcut, it is a trade-off that rarely works in the patient's favour.

Your prescriber sets the pace. If side effects are mild and you are tolerating each dose well, the four-week intervals are a minimum, not a mandatory wait. Equally, if a particular dose is causing persistent nausea, staying at that level for longer is a clinically reasonable choice your prescriber can guide you through.

What each dose in the schedule is actually doing

The five licensed steps for standard Wegovy (0.25mg, 0.5mg, 1.0mg, 1.7mg and 2.4mg) are not arbitrary. Each increment moves progressively closer to the concentration at which semaglutide produces consistent appetite suppression and blood-sugar modulation in most adults.

Our Wegovy 0.25mg instructions page is worth bookmarking before you begin, covering what to expect during that settling-in period and how to use your first pen correctly. Some people feel barely any effect; others notice mild nausea within the first day or two of each new pen. That is normal, and it usually settles within a week. The 0.5mg and 1.0mg steps are where many patients first notice reduced appetite, smaller portions feel satisfying, and the urge to snack between meals fades. By 1.7mg and 2.4mg, the therapeutic effect is typically well established, and this is where most of the trial evidence is concentrated.

For the full picture of what each Wegovy dose involves, including the newer 7.2mg approval, there is more detail in our dedicated dose guide. The 7.2mg option (approved by the MHRA in April 2026 as a single-dose pen for adults with a BMI of 30 or above) is reached via the same gradual titration pathway; it does not bypass the earlier steps. Whether it is appropriate for you is a clinical decision made with your prescriber, not something to request based on trial headlines alone.

Injection technique matters throughout. Wegovy is a subcutaneous injection given into the abdomen, thigh or upper arm, rotating sites each week. Injecting into the same spot repeatedly can cause localised tissue changes that affect absorption. The Wegovy four-dose pen instructions walk through the injection process in detail if that is useful.

When the schedule gets disrupted, illness, holidays, life

Real life does not follow a tidy four-week calendar. Bank holidays, illness, delayed deliveries and the occasional miscalculation about when a pen will run out all interrupt the ideal schedule. Knowing in advance what to do makes those disruptions much less stressful.

The golden rule for a forgotten or missed dose: do not double up. Taking two doses close together to compensate increases the risk of side effects without meaningfully improving the week's therapeutic effect. Our Wegovy missed-dose guidance covers the specifics, whether to take the missed dose or skip it depends on how many days remain until the next scheduled injection.

Travel and storage are worth thinking through ahead of time, especially around bank holidays when deliveries and pharmacy collections might shift by a day or two. Wegovy requires refrigeration, and any period outside the recommended temperature range affects the medicine's integrity. The Patient Information Leaflet states the exact room-temperature window; that is the document to consult, not forum advice.

If you are considering taking a break from treatment for a planned reason (surgery, for example) tell your prescriber well in advance. NHS England's guidance on weight-management injections advises patients to inform their healthcare team, including their anaesthetist, that they are taking a GLP-1 medicine before any surgical procedure. This is not a formality; it has practical implications for anaesthetic management.

Pausing and restarting treatment after a longer gap may mean returning to a lower dose, rather than picking up where you left off. Your prescriber will advise on the safest approach. The semaglutide injection dosage overview has more on what restarting typically involves.

Side effects that are part of the schedule, and those that are not

Nausea is the most common side effect of Wegovy and tends to cluster around dose increases. For most people it is manageable, peaking in the first few days after moving up and then fading. Constipation, indigestion and fatigue appear in a smaller but meaningful proportion of patients and similarly tend to settle as the body adjusts.

These are expected parts of the titration experience. They are not signs that treatment is failing or that the dose is wrong. Eating smaller meals, avoiding high-fat or spicy food in the first weeks of a new dose, and staying well hydrated all help, though for specific advice on managing side effects, your prescriber or the Patient Information Leaflet is the right source.

A smaller set of symptoms should prompt medical attention rather than watchful waiting. Severe abdominal pain that radiates to the back, with or without vomiting, needs to be assessed urgently, this is the presentation flagged in the MHRA's January 2026 Drug Safety Update on GLP-1 medicines and acute pancreatitis. Signs of a serious allergic reaction, gallbladder symptoms or significant dehydration from persistent vomiting and diarrhoea also warrant prompt contact with a healthcare professional.

If you are unsure whether what you are experiencing falls into the expected category, our team is available seven days a week. You can also reach our aftercare team directly if you are an existing patient. Suspected side effects can be reported to the MHRA via the Yellow Card scheme, which actively monitors GLP-1 medicines. Wegovy carries a Black Triangle (▼) designation, meaning it is under additional MHRA surveillance, your reports contribute to the real-world safety picture.

For anyone at the stage of weighing up whether Wegovy is the right option, our weight-loss treatment overview covers the broader landscape. When you are ready to find out whether you are clinically suitable, check your eligibility with a free consultation, reviewed the same day by a GPhC-registered prescriber.